Organoid and Spheroid Tumor Models: Techniques and Applications.
Gunti S, Hoke ATK, Vu KP, London NR. · 2021
Read Organoid and Spheroid Tumor Models: Techniques and Applications. by Gunti S, Hoke ATK, Vu KP, London NR. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7922036.txt.
Introduction
Gunti and co-authors present a review of organoid and spheroid tumour models. Both models grow cancer cells in three dimensions, closer to real tissue than flat cultures. They differ in their cell sources and in how they are set up. Grown from a patient's tumour, they keep many traits of the original growth.
Spheroids are simpler in structure and popular for drug screening. Organoids match the source tumour in both form and genetics. They can be kept alive long term and frozen in biobanks. Testing chemo-, radio-, and immunotherapies on them may predict how the patient will respond. Chip versions add flow and tissue-to-tissue contact for a closer match to the body. The review compares the models' methods and latest uses. It frames them as a bridge between flat cultures and animal work.
Catalog record
| CREATOR | Gunti S, Hoke ATK, Vu KP, London NR. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 63 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Organoid and Spheroid Tumor Models: Techniques and Applications By Sreenivasulu Gunti, Austin T.K. Hoke, Kenny P. Vu, Nyall R. London, Masako Nakanishi, Mary Frances McMullin Published in: Cancers DOI: 10.3390/cancers13040874 ABSTRACT Simple Summary Cell cultures can be carried out in three dimensions (3D). Organoids and spheroids are different 3D cell culture models that can be cultured with different techniques. These 3D cell culture units established from a patient tumor have several similarities to the original tumor tissue and possess several advantages in conducting basic and clinical cancer research. Organoids prepared from a patient tissue can be preserved in a living biobank. Testing chemo-, radio- and immuno-therapies on these organoids has the potential to predict the patient responses and these models have incredible promise for personalized medicine. This review presents different organoid models, the techniques to prepare them and recent advances in their applications. Abstract Techniques to develop three-dimensional cell culture models are rapidly expanding to bridge the gap between conventional cell culture and animal models. Organoid and spheroid cultures have distinct and overlapping purposes and differ in cellular sources and protocol for establishment. Spheroids are of lower complexity structurally but are simple and popular models for drug screening. Organoids histologically and genetically resemble the original tumor from which they were derived. Ease of generation, ability for long-term culture and cryopreservation make organoids suitable for a wide range of applications. Organoids-on-chip models combine organoid methods with powerful designing and fabrication of micro-chip technology. Organoid-chip models can emulate the dynamic microenvironment of tumor pathophysiology as well as tissue–tissue interactions. In this review, we outline different tumor spheroid and organoid models and techniques to establish them. We also discuss the recent advances and applications of tumor organoids with an emphasis on tumor modeling, drug screening, personalized medicine and immunotherapy. 1. INTRODUCTION Cancer represents the second most leading cause of death globally, accounting for one in six deaths according to the World Health Organization (WHO) [1]. In the past decade, significant advances have been made in cancer research in terms of diagnosis and treatment. However, a large proportion of drugs fail at the development stage and only a few drugs reach the market for clinical use. The high attrition rates are in part due to failure to meet safety requirements or from lack of efficacy in clinical trials [2]. For example, a drug that appears to be safe in animal models can show unacceptable toxicities in humans, thus leading to withdrawal. One of the major obstacles in developing drugs in a time- and cost-effective manner is the lack of preclinical cancer models that resemble the complexity of human tumors. Two-dimensional (2D) cell culture has significantly advanced several areas of research and remains a predominant pre-clinical method [3]. Cell culture methods are relatively simple, economic and are amenable to high-throughput drug screening and toxicity studies. However, 2D cell cultures are oversimplified versions of tumors, and do not recapitulate all the essential cellular organization and interactions that occur in vivo. The success rate of establishment of cell lines for some cancer types is very low. Moreover, cell lines often lose cellular heterogeneity observed in tumors upon long-term culture. On the other hand, patient-derived tumor xenografts (PDTX) resemble the tumor in cellular complexity and can retain tumor heterogeneity. PDTXs are often implanted in immunodeficient hosts and thus require reconstitution of autologous immune cells if immunity is studied. The low implantation-take rates, duration of immune reconstitution, cost and time to generate humanized models are major limitations of PDTXs [4] (Table 1). However, cancer is a highly heterogenous disease and the tumor microenvironment (TME) is complex and dynamic. Both cellular (tumor epithelium, fibroblasts, stem cells, endothelial cells and tumor-infiltrating immune cells) and non-cellular components (extra cellular matrix (ECM), cytokines, chemokines and growth factors) of the TME play a crucial role in tumor development and progression and thus could play a critical role in the outcome of drug development [5]. Therefore, pre-clinical models that recapitulate tumor pathophysiology in vivo are critical for the accurate assessment of drug efficacy and toxicity. Three-dimensional cell culture techniques have emerged as a promising method to bridge the gap between cell culture and animal models. Various 3D models have been developed, including tissue explants, spheroids and the recently expanding field of organoids. The terms organoids, spheroids and 3D cell cultures have been used interchangeably in the literature [6]. Spheroids are spherical cellular units that are generally cultured as free-floating aggregates and are arguably of low complexity in mirroring tumor organization. In general, organoids can be referred to as cells grown in 3D to form structural units that partially resemble the organ, both in structure and function [7]. 3D cultures can be established either using support of an ECM (scaffold-based) or without the use of a scaffold (scaffold-free). Spheroids and organoid culture models have distinct and overlapping purposes and they differ in terms of tumor cell sources, protocol for culture and the time required for establishment (Table 2). Organoids can be expanded for long-term culture and can be cryopreserved. Organoids resemble the original tissue both histologically and genetically. In addition, organoids can be cultured from a very small amount of tissue and are amenable to genetic manipulations [8,9]. These features allow their use for a wide range of applications in cancer research, including the study of carcinogenesis, drug development and personalized medicine. In this review, we highlight different models of spheroids and organoids based on their cellular sources and methods of generation, including static and microfluidic flow-based chip methods. We focus on recent progress in the application of tumor organoids in cancer modeling, drug development, personalized cancer medicine and immunotherapy. Applications of spheroids from different cellular sources have been reviewed extensively elsewhere and hence we mainly focus on tumor-derived organoids. However, we include recent literature on tumor-derived spheroids in respective sections [10,11,12]. Finally, we conclude with merits and challenges of organoid technology in cancer biology. 2. SPHEROID MODELS AND METHODS Spheroids were first introduced in the early 1970s by Sutherland and colleagues [13]. Since then, different spheroid models and methods to generate them have been developed. Spheroids form by spontaneous aggregation of cells followed by binding of cell surface integrins to the ECM. After initial cell–cell contact, cells upregulate E-Cadherin which accumulates on the cell surface and then the spheroid becomes a compact structure through strong intercellular E-cadherin interactions [14,15]. This process is impacted by various factors including nutrients, oxygen and growth factors [16]. Different spheroid models have been described based on their cellular sources. Multicellular tumor spheroids (MCTS) are often made from cancer cell lines, but rarely from tumor tissues. MCTS show little histological resemblance to the original tumor, but they mimic metabolic and proliferation gradients of the in vivo tumor and model clinically relevant resistance to chemotherapy. The advantages of MCTS are that they are clonal, simple to expand into large cultures and suitable for high-throughput systems [17]. Tumor-derived spheroids are prepared from mechanical or enzymatic dissociation of tumor tissue into a single cell suspension, followed by culture in serum or serum-free media. Tumor-derived spheroids have been prepared from brain [18], breast [19], lung [20], colon [21], prostate [22], pancreas [23] and ovarian tumors [24]. Culture in serum-free media containing different growth factors such